» Articles » PMID: 39156157

Infectious Disease Prophylaxis During and After Immunosuppressive Therapy

Overview
Journal Kidney Int Rep
Publisher Elsevier
Specialty Nephrology
Date 2024 Aug 19
PMID 39156157
Authors
Affiliations
Soon will be listed here.
Abstract

Immune-mediated renal diseases are a diverse group of disorders caused by antibody, complement, or cell-mediated autosensitization. Although these diseases predispose to infection on their own, a growing array of traditional and newer, more targeted immunosuppressant medications are used to treat these diseases. By understanding their mechanisms of action and the infections associated with suppression of each arm of the immune system, nephrologists can better anticipate these risks and effectively prevent and recognize opportunistic infections. Focusing specifically on nonkidney transplant recipients, this review discusses the infections that can be associated with each of the commonly used immunosuppressants by nephrologists and suggest interventions to prevent infectious complications in patients with immune-mediated renal disease.

References
1.
Danziger-Isakov L, Kumar D . Vaccination of solid organ transplant candidates and recipients: Guidelines from the American society of transplantation infectious diseases community of practice. Clin Transplant. 2019; 33(9):e13563. DOI: 10.1111/ctr.13563. View

2.
Barkati S, Greenaway C, Libman M . Strongyloidiasis in immunocompromised migrants to non-endemic countries in the era of COVID-19: what is the role for presumptive ivermectin?. J Travel Med. 2021; 29(1). PMC: 8500134. DOI: 10.1093/jtm/taab155. View

3.
Buonfrate D, Bisanzio D, Giorli G, Odermatt P, Furst T, Greenaway C . The Global Prevalence of Infection. Pathogens. 2020; 9(6). PMC: 7349647. DOI: 10.3390/pathogens9060468. View

4.
Miyake K, Kawamura T, Nakahara Y, Sasaki S . A single-center, person-month-based analysis of the risk of developing Pneumocystis pneumonia (PCP) in immunosuppressed non-HIV patients: Preventive effects of trimethoprim-sulfamethoxazole. J Infect Chemother. 2023; 29(12):1097-1102. DOI: 10.1016/j.jiac.2023.07.012. View

5.
Barmettler S, Ong M, Farmer J, Choi H, Walter J . Association of Immunoglobulin Levels, Infectious Risk, and Mortality With Rituximab and Hypogammaglobulinemia. JAMA Netw Open. 2019; 1(7):e184169. PMC: 6324375. DOI: 10.1001/jamanetworkopen.2018.4169. View